Building on comprehensive work of a former ANSTO researcher Prof Suzanne Smith, Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has progressed its lead product SARTATE™ from the lab into the clinic for treatment of a range of cancers including neuroendocrine tumours and childhood cancers. The product, a promising molecular imaging…
Clarity Pharmaceuticals pioneers world first use of copper radioisotopes for diagnosis, dosimetry and treatment of cancer Sydney, Australia, 24 May 2016 – Clarity Pharmaceuticals, an emerging Australian biotech company specialising in the treatment of serious disease, has raised AU$2 million to develop its clinical pipeline using its proprietary drug targeting technology. The investment round includes…
Sydney, Australia 11 April 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the results of its clinical trial data for its lead product SARTATE™ will be presented by its collaborators at the Peter MacCallum Cancer Centre at the 2016 Society of Nuclear Medicine and Molecular…
Sydney, Australia 29 March 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Chris Roberts as an independent Non-Executive Director of the Company. Dr Roberts has over 40 years’ experience in the medical innovation space and has served on the boards…
Sydney, Australia 18 March 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded the maximum amount of Accelerating Commercialisation grant funding. This grant is part of the Australian Government’s Entrepreneurs’ Programme and will be used to commercialise Clarity’s novel radiopharmaceutical for treating cancer, SARTATE™. The grant, valued…
Sydney, Australia 18 December 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded a Research Connections Grant under the Entrepreneurs’ Programme. The grant, valued at $50,000, will go toward funding the employment of Australian scientist Charmaine Jeffery as Preclinical Development Manager, who will be responsible for conducting…
Sydney, Australia 16 October 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded a Business Growth Grant under the Entrepreneurs’ Programme. The grant, valued at $20,000, will help fund Clarity’s drug development pipeline project plan. The grant will be used to provide funding to engage Dr Ellen…
“Imaging technology is guiding cutting edge drug development.” Clarity Pharmaceuticals was featured in dealflow, the publication for the Entrepreneurs’ Programme which profiles some of the best performing and highest potential businesses that have received commercialisation support from the Australian Government. “Today’s biopharmaceutical companies are under pressure to meet the demand for more personalised therapies, where…
Clarity and University of Melbourne receive Australian Research Council Grant funding for novel diagnostic imaging research Sydney, Australia 5 August 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been co-awarded a prominent Australian Research Council (ARC) Linkage Grant with the University of Melbourne. The grant, valued at $365,000…
Sydney, Australia, 8 April 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has signed a licensing agreement with Baker IDI Heart and Diabetes Institute (Melbourne, Australia) to develop a diagnostic for the detection of rupture-prone plaque. The importance of detecting unstable, rupture-prone plaque, especially to prevent recurrent heart attacks,…